Disease ID | Disease name | Source of annotation with PIK3CD | OMIM link | Number of associated genes | genes |
---|---|---|---|---|---|
615513 | IMMUNODEFICIENCY 14 | ClinVar, OMIM, HUMSAVAR | link to OMIM | 1 | PIK3CD |
Download the gene annotation in CSV format
KEGG pathway | KEGG ID | KEGG IC |
---|---|---|
Melanoma | hsa05218 | 6.56 |
Platelet activation | hsa04611 | 5.66 |
Fc gamma R-mediated phagocytosis | hsa04666 | 6.21 |
Small cell lung cancer | hsa05222 | 6.17 |
cGMP-PKG signaling pathway | hsa04022 | 5.32 |
Natural killer cell mediated cytotoxicity | hsa04650 | 5.53 |
Colorectal cancer | hsa05210 | 6.52 |
Renal cell carcinoma | hsa05211 | 6.6 |
Jak-STAT signaling pathway | hsa04630 | 5.44 |
Signaling pathways regulating pluripotency of stem cells | hsa04550 | 5.6 |
cAMP signaling pathway | hsa04024 | 5.05 |
Prostate cancer | hsa05215 | 6.11 |
Leukocyte transendothelial migration | hsa04670 | 5.74 |
Cholinergic synapse | hsa04725 | 5.88 |
Choline metabolism in cancer | hsa05231 | 6.09 |
FoxO signaling pathway | hsa04068 | 5.63 |
Osteoclast differentiation | hsa04380 | 5.64 |
HIF-1 signaling pathway | hsa04066 | 5.9 |
Chemokine signaling pathway | hsa04062 | 5.19 |
Oxytocin signaling pathway | hsa04921 | 5.4 |
Inositol phosphate metabolism | hsa00562 | 6.72 |
Aldosterone-regulated sodium reabsorption | hsa04960 | 7.41 |
VEGF signaling pathway | hsa04370 | 6.77 |
Focal adhesion | hsa04510 | 4.92 |
Endometrial cancer | hsa05213 | 6.81 |
Type II diabetes mellitus | hsa04930 | 7.12 |
Progesterone-mediated oocyte maturation | hsa04914 | 6.18 |
Chagas disease (American trypanosomiasis) | hsa05142 | 5.99 |
Pancreatic cancer | hsa05212 | 6.56 |
Amoebiasis | hsa05146 | 5.82 |
Epstein-Barr virus infection | hsa05169 | 4.97 |
Toxoplasmosis | hsa05145 | 5.71 |
Influenza A | hsa05164 | 5.21 |
Apoptosis | hsa04210 | 6.23 |
HTLV-I infection | hsa05166 | 4.59 |
PI3K-Akt signaling pathway | hsa04151 | 4.21 |
Hepatitis C | hsa05160 | 5.68 |
Hepatitis B | hsa05161 | 5.52 |
Measles | hsa05162 | 5.6 |
B cell receptor signaling pathway | hsa04662 | 6.52 |
Chronic myeloid leukemia | hsa05220 | 6.48 |
Bacterial invasion of epithelial cells | hsa05100 | 6.34 |
Proteoglycans in cancer | hsa05205 | 5.02 |
Toll-like receptor signaling pathway | hsa04620 | 6.0 |
Pathways in cancer | hsa05200 | 3.98 |
Viral carcinogenesis | hsa05203 | 5.08 |
T cell receptor signaling pathway | hsa04660 | 6.01 |
Phosphatidylinositol signaling system | hsa04070 | 6.38 |
Rap1 signaling pathway | hsa04015 | 4.97 |
Ras signaling pathway | hsa04014 | 4.9 |
Inflammatory mediator regulation of TRP channels | hsa04750 | 6.07 |
Prolactin signaling pathway | hsa04917 | 6.6 |
Acute myeloid leukemia | hsa05221 | 6.74 |
Estrogen signaling pathway | hsa04915 | 6.11 |
TNF signaling pathway | hsa04668 | 5.96 |
Thyroid hormone signaling pathway | hsa04919 | 5.82 |
AMPK signaling pathway | hsa04152 | 5.8 |
mTOR signaling pathway | hsa04150 | 6.72 |
Regulation of actin cytoskeleton | hsa04810 | 4.9 |
Carbohydrate digestion and absorption | hsa04973 | 7.28 |
Non-small cell lung cancer | hsa05223 | 6.88 |
Insulin signaling pathway | hsa04910 | 5.55 |
Neurotrophin signaling pathway | hsa04722 | 5.78 |
Non-alcoholic fatty liver disease (NAFLD) | hsa04932 | 5.51 |
Central carbon metabolism in cancer | hsa05230 | 6.7 |
Glioma | hsa05214 | 6.66 |
Fc epsilon RI signaling pathway | hsa04664 | 6.6 |
Adrenergic signaling in cardiomyocytes | hsa04261 | 5.44 |
ErbB signaling pathway | hsa04012 | 6.15 |
REACTOME pathway | REACTOME ID | REACTOME IC |
---|---|---|
Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 7.94 |
PI3K/AKT activation | R-HSA-198203 | 6.32 |
Signaling by Interleukins | R-HSA-449147 | 4.71 |
Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.62 |
GPVI-mediated activation cascade | R-HSA-114604 | 7.18 |
Immune System | R-HSA-168256 | 2.37 |
Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 7.05 |
PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.37 |
Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 |
Platelet activation, signaling and aggregation | R-HSA-76002 | 5.15 |
Metabolism | R-HSA-1430728 | 2.34 |
Downstream signal transduction | R-HSA-186763 | 4.65 |
GAB1 signalosome | R-HSA-180292 | 6.31 |
PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.37 |
Signaling by ERBB4 | R-HSA-1236394 | 4.7 |
Adaptive Immune System | R-HSA-1280218 | 3.19 |
Disease | R-HSA-1643685 | 3.33 |
Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 4.95 |
Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 |
Signalling by NGF | R-HSA-166520 | 4.23 |
PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.37 |
PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.37 |
Phospholipid metabolism | R-HSA-1483257 | 5.83 |
PI Metabolism | R-HSA-1483255 | 7.31 |
Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.59 |
Metabolism of lipids and lipoproteins | R-HSA-556833 | 3.79 |
Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 |
Signaling by FGFR4 | R-HSA-5654743 | 4.69 |
Signaling by FGFR3 | R-HSA-5654741 | 4.69 |
Signaling by FGFR | R-HSA-190236 | 4.67 |
PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.56 |
Diseases of signal transduction | R-HSA-5663202 | 4.89 |
Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 |
GPCR downstream signaling | R-HSA-388396 | 3.07 |
Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 |
Innate Immune System | R-HSA-168249 | 3.17 |
Signaling by SCF-KIT | R-HSA-1433557 | 4.73 |
Interleukin-2 signaling | R-HSA-451927 | 5.05 |
Signaling by ERBB2 | R-HSA-1227986 | 4.66 |
G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 7.4 |
DAP12 signaling | R-HSA-2424491 | 4.64 |
Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 |
Regulation of signaling by CBL | R-HSA-912631 | 8.52 |
Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 |
Signaling by EGFR | R-HSA-177929 | 4.59 |
NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 5.6 |
PIP3 activates AKT signaling | R-HSA-1257604 | 6.37 |
Signaling by GPCR | R-HSA-372790 | 2.68 |
Signaling by FGFR2 | R-HSA-5654738 | 4.68 |
Signaling by FGFR1 | R-HSA-5654736 | 4.69 |
PI3K events in ERBB4 signaling | R-HSA-1250342 | 6.37 |
G-protein beta:gamma signalling | R-HSA-397795 | 7.31 |
PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.37 |
DAP12 interactions | R-HSA-2172127 | 4.56 |
Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 |
Signaling by PDGF | R-HSA-186797 | 4.53 |
Hemostasis | R-HSA-109582 | 3.98 |
Signal Transduction | R-HSA-162582 | 1.78 |
GO term | GO ID | GO IC |
---|---|---|
purine ribonucleoside triphosphate binding | GO:0035639 | 2.22 |
binding | GO:0005488 | 0.18 |
phosphatidylinositol 3-kinase activity | GO:0035004 | 5.49 |
1-phosphatidylinositol-4-phosphate 3-kinase activity | GO:0035005 | 7.79 |
heterocyclic compound binding | GO:1901363 | 1.06 |
purine nucleoside binding | GO:0001883 | 2.22 |
nucleoside binding | GO:0001882 | 2.21 |
phosphatidylinositol-4,5-bisphosphate 3-kinase activity | GO:0046934 | 5.61 |
nucleotide binding | GO:0000166 | 1.96 |
phosphatidylinositol bisphosphate kinase activity | GO:0052813 | 5.56 |
transferase activity | GO:0016740 | 1.95 |
nucleoside phosphate binding | GO:1901265 | 1.96 |
ribonucleoside binding | GO:0032549 | 2.22 |
purine nucleotide binding | GO:0017076 | 2.19 |
ATP binding | GO:0005524 | 2.43 |
1-phosphatidylinositol-3-kinase activity | GO:0016303 | 5.98 |
kinase activity | GO:0016301 | 2.93 |
phosphatidylinositol phosphate kinase activity | GO:0016307 | 6.97 |
small molecule binding | GO:0036094 | 1.89 |
catalytic activity | GO:0003824 | 1.05 |
phosphotransferase activity, alcohol group as acceptor | GO:0016773 | 3.08 |
adenyl nucleotide binding | GO:0030554 | 2.4 |
phosphatidylinositol kinase activity | GO:0052742 | 5.81 |
organic cyclic compound binding | GO:0097159 | 1.05 |
carbohydrate derivative binding | GO:0097367 | 2.03 |
adenyl ribonucleotide binding | GO:0032559 | 2.41 |
protein binding | GO:0005515 | 0.46 |
transferase activity, transferring phosphorus-containing groups | GO:0016772 | 2.77 |
purine ribonucleotide binding | GO:0032555 | 2.2 |
purine ribonucleoside binding | GO:0032550 | 2.22 |
ribonucleotide binding | GO:0032553 | 2.19 |